Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations: 2012-2024

Historic Cash from Operations for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to -$134.7 million.

  • Ocular Therapeutix's Cash from Operations fell 38.75% to -$50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.1 million, marking a year-over-year decrease of 61.48%. This contributed to the annual value of -$134.7 million for FY2024, which is 91.75% down from last year.
  • As of FY2024, Ocular Therapeutix's Cash from Operations stood at -$134.7 million, which was down 91.75% from -$70.2 million recorded in FY2023.
  • Ocular Therapeutix's 5-year Cash from Operations high stood at -$53.6 million for FY2020, and its period low was -$134.7 million during FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$70.2 million (2023), whereas its average is -$88.2 million.
  • Per our database at Business Quant, Ocular Therapeutix's Cash from Operations skyrocketed by 30.97% in 2020 and then crashed by 91.75% in 2024.
  • Ocular Therapeutix's Cash from Operations (Yearly) stood at -$53.6 million in 2020, then fell by 22.40% to -$65.5 million in 2021, then grew by 9.07% to -$59.6 million in 2022, then fell by 17.84% to -$70.2 million in 2023, then slumped by 91.75% to -$134.7 million in 2024.